Title : A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure.

Pub. Date : 2019 Sep 27

PMID : 31484861






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Tolvaptan, a vasopressin V2 receptor antagonist, is approved in Japan for the treatment of fluid retention in patients with heart failure (HF), and in the United States for hyponatremia. Tolvaptan arginine vasopressin receptor 2 Homo sapiens